Alaunos Therapeutics Statistics
Total Valuation
TCRT has a market cap or net worth of $6.16 million. The enterprise value is $5.04 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRT has 2.38 million shares outstanding. The number of shares has increased by 21.68% in one year.
| Current Share Class | 2.38M |
| Shares Outstanding | 2.38M |
| Shares Change (YoY) | +21.68% |
| Shares Change (QoQ) | +6.55% |
| Owned by Insiders (%) | 20.67% |
| Owned by Institutions (%) | 7.19% |
| Float | 1.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,284.26 |
| Forward PS | n/a |
| PB Ratio | 2.95 |
| P/TBV Ratio | 2.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,007.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.45
| Current Ratio | 2.45 |
| Quick Ratio | 1.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -198.10% and return on invested capital (ROIC) is -125.27%.
| Return on Equity (ROE) | -198.10% |
| Return on Assets (ROA) | -92.31% |
| Return on Invested Capital (ROIC) | -125.27% |
| Return on Capital Employed (ROCE) | -196.24% |
| Weighted Average Cost of Capital (WACC) | -1.98% |
| Revenue Per Employee | $5,000 |
| Profits Per Employee | -$4.28M |
| Employee Count | 1 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.52% in the last 52 weeks. The beta is -1.13, so TCRT's price volatility has been lower than the market average.
| Beta (5Y) | -1.13 |
| 52-Week Price Change | -1.52% |
| 50-Day Moving Average | 3.02 |
| 200-Day Moving Average | 2.93 |
| Relative Strength Index (RSI) | 32.94 |
| Average Volume (20 Days) | 17,256 |
Short Selling Information
The latest short interest is 12,380, so 0.52% of the outstanding shares have been sold short.
| Short Interest | 12,380 |
| Short Previous Month | 14,162 |
| Short % of Shares Out | 0.52% |
| Short % of Float | 0.66% |
| Short Ratio (days to cover) | 0.68 |
Income Statement
In the last 12 months, TCRT had revenue of $5,000 and -$4.28 million in losses. Loss per share was -$2.20.
| Revenue | 5,000 |
| Gross Profit | -1.36M |
| Operating Income | -4.23M |
| Pretax Income | -4.18M |
| Net Income | -4.28M |
| EBITDA | -4.22M |
| EBIT | -4.23M |
| Loss Per Share | -$2.20 |
Full Income StatementBalance Sheet
The company has $1.39 million in cash and n/a in debt, giving a net cash position of $1.39 million or $0.58 per share.
| Cash & Cash Equivalents | 1.39M |
| Total Debt | n/a |
| Net Cash | 1.39M |
| Net Cash Per Share | $0.58 |
| Equity (Book Value) | 2.15M |
| Book Value Per Share | 0.92 |
| Working Capital | 1.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$2.87 million and capital expenditures -$98,000, giving a free cash flow of -$2.97 million.
| Operating Cash Flow | -2.87M |
| Capital Expenditures | -98,000 |
| Depreciation & Amortization | 7,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -2.97M |
| FCF Per Share | -$1.25 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -84,500.00% |
| Pretax Margin | -83,520.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |